At NHLBI, more than 50% of the supported startups are developing medical, research, or consumer devices supported by the SBIR program. Additional innovator resources are available to companies new to NIH and those with SBIR/STTR grants. This moderated panel will discuss the strategies of maximizing non-dilutive funding as a part of the product development, successful company growth and exit.

Stephen Flaim
Senior Special Advisor & Investor-In-Residence | President | Director
National Heart Lung and Blood Institute, NIH | Flaim Partners Consulting | Haima Therapeutics

Erik Kulstad
Attending Physician | Professor of Emergency Medicine | Co-Founder
Parkland Hospital Emergency Department | University of Texas Southwestern Medical Center | Attune Medical

Erika Tyburski
Chief Executive Officer
Sanguina, Inc.

Moderator
Julia Berzhanskaya
Program Director for trans-NIH REACH 2.0 and Innovator Support Lead
National Heart Lung and Blood Institute (NHLBI) Innovation& Commercialization Office